Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: Implications for intervention studies

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 4, 2005, Pages 419-421

  Muro, Eva ^a   Droste, Jacqueline A H ^b   Ter Hofstede, Hadewych ^b   Bosch, Marjolein ^b   Dolmans, Wil ^a   Burger, David M ^b  

^a KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Developing countries; Nevirapine; Pharmacokinetics; Resistance

Indexed keywords

NEVIRAPINE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NETHERLANDS; PERINATAL PERIOD; PRIORITY JOURNAL; SINGLE DRUG DOSE; VALIDATION PROCESS; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; SALIVA;

EID: 22344443325     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000167154.37357.f9     Document Type: Article

References (9)

1. Nolan ML, Greenberg AE, Fowler MG. A review of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies. AIDS. 2002;16:1991-1999.
2. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002;4:59-63.
3. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.
4. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
5. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, Burger DM, et al. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000;744:65-71.
6. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr. 2002;29: 471-477.
7. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14(Suppl):F111-F115.
8. McIntyre J, Martinson N, Boltz V, et al. Addition of a short course of Combivir to single dose Viramune for prevention of mother-to-child transmission of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus [abstract LbOrB09]. Presented at: 15th International AIDS Conference; 2004; Bangkok.
9. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. Ther Drug Monit. 2001;23:255-258.